| __timestamp | Catalyst Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 305409000 |
| Thursday, January 1, 2015 | 8597010 | 377080000 |
| Friday, January 1, 2016 | 7910260 | 432829000 |
| Sunday, January 1, 2017 | 7304399 | 496079000 |
| Monday, January 1, 2018 | 15875961 | 557616000 |
| Tuesday, January 1, 2019 | 36881187 | 658498000 |
| Wednesday, January 1, 2020 | 44233754 | 770456000 |
| Friday, January 1, 2021 | 49628000 | 840100000 |
| Saturday, January 1, 2022 | 58183000 | 944700000 |
| Sunday, January 1, 2023 | 133710000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in this area. From 2014 to 2023, Vertex's SG&A expenses surged by approximately 272%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Catalyst Pharmaceuticals saw a staggering increase of nearly 2,889% in the same period, indicating a rapid scale-up from a smaller base.
Vertex's consistent growth in SG&A expenses, peaking at over $1.1 billion in 2023, underscores its commitment to maintaining a robust operational framework. Meanwhile, Catalyst's expenses, which reached $133 million in 2023, highlight its transition from a niche player to a more significant market contender. This data offers a fascinating glimpse into how these companies balance cost management with growth ambitions.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Alnylam Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Incyte Corporation
Vertex Pharmaceuticals Incorporated and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and MorphoSys AG
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs MannKind Corporation
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Catalyst Pharmaceuticals, Inc. Trends and Insights